SCHEMBL1035441

SCHEMBL1035441

CCCCCCCCCCCCCCC(CCCC=O)CCCCCCCCCCCCCC

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.65
FAAH O00519 2/20 0.58
TRPV1 Q8NER1 2/20 0.58
LMNA P02545 1/20 0.48
ADH1B P00325 2/20 0.45
ADH1C P00326 2/20 0.45
ADH1A P07327 2/20 0.45
ADH4 P08319 2/20 0.45
ADH7 P40394 2/20 0.45
EPHX1 P07099 1/20 0.43
ALDH1A1 P00352 1/20 0.42
MAPT P10636 2/20 0.39
TRPA1 O75762 1/20 0.39
DDAH1 O94760 1/20 0.39
GAPDH P04406 1/20 0.39
HIF1A Q16665 1/20 0.39
GPR84 Q9NQS5 3/20 0.39
FDPS P14324 3/20 0.39
FFAR1 O14842 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25907690 1.00 TSHR (0.65) TSHRFAAHTRPV1LMNAADH1B
SCHEMBL9425832 1.00 TSHR (0.65) TSHRFAAHTRPV1LMNAADH1B
SCHEMBL9260986 0.96 TSHR (0.60) TSHRFAAHTRPV1LMNAADH1B
SCHEMBL6862076 0.95 TSHR (0.58) TSHRFAAHTRPV1LMNAADH1B
SCHEMBL22602593 0.95 TSHR (0.73) TSHRFAAHTRPV1LMNAADH1B
SCHEMBL17750778 0.93 TSHR (0.56) TSHRFAAHTRPV1LMNAADH1B
SCHEMBL29109640 0.91 TSHR (0.60) TSHRFAAHTRPV1LMNAADH1B
SCHEMBL9264608 0.91 TSHR (0.67) TSHRFAAHTRPV1LMNAADH1B
SCHEMBL19759291 0.91 TSHR (0.58) TSHRFAAHTRPV1LMNAADH1B
SCHEMBL9257903 0.91 TSHR (0.58) TSHRFAAHTRPV1LMNAADH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399422-B2 Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications POLYPLUS-TRANSFECTION (FR) 2013-03-19 US disclosed
US-8399422-B2 Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications POLYPLUS-TRANSFECTION (FR) 2013-03-19 US disclosed
EP-2004156-B1 COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS POLYPLUS TRANSFECTION SA (FR) 2011-01-26 EP disclosed
US-20100048672-A1 COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS POLYPLUS-TRANSFECTION (FR) 2010-02-25 US disclosed
US-20100048672-A1 COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS POLYPLUS-TRANSFECTION (FR) 2010-02-25 US disclosed
EP-2004156-A2 COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS Polyplus-Transfection SA (FR) 2008-12-24 EP disclosed
WO-2008004058-A2 COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS POLYPLUS-TRANSFECTION SA (FR) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048672-A1 COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS C1R, C1S, C3AR1 TSHR 668/4885FAAH 1120/4885TRPV1 2018/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.